- Current report filing (8-K)
30 3월 2012 - 10:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
March 30, 2012
Synthetic Biologics, Inc.
(Exact name of registrant as specified in
charter)
Nevada
(State or other jurisdiction of incorporation)
01-12584
(Commission File Number)
|
13-3808303
(IRS Employer Identification No.)
|
3985 Research Park Drive, Suite 200
Ann Arbor, MI 48108
(Address of principal executive offices
and zip code)
(734) 332-7800
(Registrant’s telephone number including
area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02 – Results of Operations and Financial Condition.
On March 30, 2012, Synthetic Biologics, Inc., a Nevada corporation
(the “Registrant"), issued the attached press release that included financial information for its fiscal year ended
December 31, 2011. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information
contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any
of the Registrant’s registration statements or other filings with the Commission.
Item 9.01
Financial Statements and Exhibits.
(d)
|
Exhibits.
|
|
|
|
Exhibit 99.1 Press Release issued by Synthetic Biologics, Inc. dated March 30, 2012
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 30, 2012
|
SYNTHETIC BIOLOGICS, INC.
|
|
(Registrant)
|
|
|
|
By:
/s/ C. Evan Ballantyne
|
|
Name: C. Evan Ballantyne
|
|
Title: Chief Financial Officer
|
EXHIBIT INDEX
Exhibit No .
|
Exhibits.
|
|
|
99.1
|
Press Release issued by Synthetic Biologics, Inc. dated March 30, 2012
|
Synthetic Biologics (AMEX:SYN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Synthetic Biologics (AMEX:SYN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Synthetic Biologics Inc (아메리카 증권거래소)의 실시간 뉴스: 최근 기사 0
More News Articles